Neuronetics, Inc. (STIM)

NGM – Real Time Price. Currency in USD

1.34

+0.07 (5.51%)

At close: Jun 26, 2026, 4:00 PM EDT

1.34

0.00 (0.00%)

After-hours: Jun 26, 2026, 6:30 PM EDT

02.06.2026

Neuronetics Appoints Robert Greene as Senior Vice President Sales

02.06.2026

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting, where real-world data from the Company's proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on advancing the understanding of transcranial magnetic stimulation (TMS) for mental health conditions.

14.05.2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced a strategic partnership with ANT Neuro, a global leader in precision brain mapping and neuronavigation technologies, to expand the capabilities of the NeuroStar® Advanced Therapy System with advanced image-guided navigation technology.

05.05.2026

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

05.05.2026

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.

05.05.2026

Neuronetics Reports First Quarter 2026 Financial and Operating Results

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026.

29.04.2026

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

Videos

No Data

There is no data to display

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

05.05.2026

Neuronetics, Inc. (STIM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Neuronetics, Inc. (STIM)

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Search stocks

Neuronetics, Inc. (STIM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Neuronetics, Inc. (STIM)

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics Reports First Quarter 2026 Financial and Operating Results